Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors

Interleukin-1 (IL-1) inhibitors are approved for treating familial Mediterranean fever (FMF) that is resistant to colchicine. However, continued concomitant treatment with colchicine is imperative, as it is the only drug proven to prevent secondary amyloidosis. We aimed to compare the adherence to c...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in arthritis and rheumatism 2023-08, Vol.61, p.152211-152211, Article 152211
Main Authors: Levinsky, Yoel, Azani, Liat, Shkalim Zemer, Vered, Chodick, Gabriel, Tal, Rotem, Harel, Liora, Amarilyo, Gil
Format: Article
Language:English
Subjects:
Amyloidosis - drug therapy
Amyloidosis - prevention & control
Autoinflammatory diseases
Colchicine
Colchicine - pharmacology
Colchicine - therapeutic use
Familial mediterranean fever
Familial Mediterranean Fever - diagnosis
Familial Mediterranean Fever - drug therapy
Health services research
Humans
Interleukin-1
Medication adherence
Research Design
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin-1 (IL-1) inhibitors are approved for treating familial Mediterranean fever (FMF) that is resistant to colchicine. However, continued concomitant treatment with colchicine is imperative, as it is the only drug proven to prevent secondary amyloidosis. We aimed to compare the adherence to colchicine between patients with colchicine-resistant FMF (crFMF) who were treated with IL-1 inhibitors and patients with colchicine-sensitive FMF (csFMF) who were treated only with colchicine. The databases of Maccabi Health Services, a 2.6-million-member state-mandated health provider in Israel were searched for patients with FMF diagnosis. The medication possession ratio (MPR), calculated from the day of the first colchicine purchase (index date) until the last colchicine purchase was the main outcome measure. Patients with crFMF were matched in a 1:4 ratio to patients with csFMF. The final cohort included 4526 patients. Of them, 108 (2.4%) were with crFMF, and were matched to 432 with csFMF. The total mean MPR in each of the matched groups was similar (78.9 ± 41.4 and 82.5 ± 80.6, respectively, P = 0.5). Statistically significant differences in MPR were not found between the groups according to age or duration of colchicine use. However, adherence to colchicine was insufficient (MPR
ISSN:0049-0172
1532-866X
DOI:10.1016/j.semarthrit.2023.152211